Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.

Sean WhartonChristiane L HaaseElham KamranAiden LiuJohanna ManciniDrew NeishArash PaksereshtG Sarah PowerRebecca A G Christensen

Published in: Obesity science & practice (2020)

These findings suggest that real-world treatment with liraglutide 3.0 mg, regardless of obesity class, is associated with similar clinically significant weight loss, time to maintenance dose and medication persistence.

Keyphrases

weight loss
bariatric surgery
roux en y gastric bypass
gastric bypass
randomized controlled trial
weight gain
glycemic control
insulin resistance
systematic review
obese patients
metabolic syndrome
type diabetes